Similarly, bevacizumab is another monoclonal anti-VEGF antibody (VEGF-A), that is intravenously administered to treat ADM.111,112 Studies have shown that bevacizumab had significant effects on improving the status of patients with ADM and no significant adverse effects were observed.113,114 Aflibercept (Eylea) is a potent recombinant fusion VEGF protein (PLGF, VEGF-A, VEGF-B) that is used to treat colorectal cancer, AMD, diabetic macular edema, diabetic retinopathy, and macular edema. This evidence concerns the gene VEGFA and macular retinal edema.